Aptahem AB Logo

Aptahem AB

Develops RNA aptamers to treat acute, life-threatening conditions like sepsis.

APTA | SPGR

Overview

Corporate Details

ISIN(s):
SE0022447173 (+2 more)
LEI:
549300IVD1BY4CJMSO40
Country:
Sweden
Address:
Norra Vallgatan 58, 211 22 Malmö
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Aptahem AB is a clinical-stage biotechnology company that develops RNA-based pharmaceuticals, known as aptamers, for the treatment of acute, life-threatening conditions involving a combination of coagulation, inflammation, and tissue damage. The company's lead candidate, Apta-1, is in clinical development with a primary indication for sepsis, a condition with a significant unmet medical need and high mortality. Apta-1 features a unique multi-mechanistic profile to address the complex pathology of sepsis. Aptahem's technology leverages synthetically produced aptamers, which offer a highly specific and low-immunogenicity alternative to traditional antibodies.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Aptahem AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Aptahem AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Aptahem AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Replek AD Logo
Manufactures & distributes generic medicines, supplements, and cosmetic products to over 25 countries.
North Macedonia REPL
Respiratorius AB Logo
Develops oncology pre-treatment drugs to enhance the efficacy of standard cancer therapies.
Sweden RESP
REVELATION BIOSCIENCES, INC. Logo
Develops therapies that reprogram the innate immune system to reduce inflammation-related damage.
United States of America REVB
REVIVA PHARMACEUTICALS HOLDINGS, INC. Logo
Clinical-stage biopharma developing novel therapies for CNS, respiratory, and metabolic diseases.
United States of America RVPH
Revolution Medicines, Inc. Logo
A clinical-stage oncology company developing targeted therapies for RAS-addicted cancers.
United States of America RVMD
REVVITY, INC. Logo
Provides life sciences & diagnostics technologies to support workflows from discovery to cure.
United States of America RVTY
REYON PHARMACEUTICAL CO., LTD Logo
Develops & makes APIs, generics, cell/gene therapies, and offers biopharma CDMO services.
South Korea 102460
Rezolute, Inc. Logo
Developing therapies for rare metabolic diseases, focusing on hyperinsulinism-caused hypoglycemia.
United States of America RZLT
RHYTHM PHARMACEUTICALS, INC. Logo
Develops precision medicines for rare genetic diseases causing severe obesity and hyperphagia.
United States of America RYTM
RIGEL PHARMACEUTICALS INC Logo
Develops and commercializes small-molecule drugs for hematology, cancer, and autoimmune diseases.
United States of America RIGL

Talk to a Data Expert

Have a question? We'll get back to you promptly.